O-<wbr/>1602

O-1602

CAT N°: 10006803
Price:

From 43.00 36.55

O-1602 is an agonist of GPR55 (EC50 = 13 nM in a GTP?S binding assay) and a derivative of the GPR55 agonist abnormal cannabidiol (Item No. 10004259).{17583} It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 µM for both in GTP?S binding assays). O-1602 (50 µM) reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells and reduces tumor growth in a Mz-ChA-1 mouse xenograft model when administered at a dose of 10 mg/kg per day.{38346} O-1602 increases calcium mobilization and lipogenesis in 3T3-L1 adipocytes in a concentration-dependent manner and increases food intake and fat mass in rats; however, this effect was also observed in mice lacking GPR55.{38347} O-1602 reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain.{38344} It also decreases IL-6 and TNF-? levels and myeloperoxidase activities in the plasma, lungs, and pancreas in a mouse model of acute pancreatitis.{38345}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol
  • Correlated keywords
    • O162 CB 1 2 GPR-55 MzChA1 HuCCT1 CCLP1 SG 231 3T3L1 IL6 TNF? cholangio carcinoma
  • Product Overview:
    O-1602 is an agonist of GPR55 (EC50 = 13 nM in a GTP?S binding assay) and a derivative of the GPR55 agonist abnormal cannabidiol (Item No. 10004259).{17583} It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 µM for both in GTP?S binding assays). O-1602 (50 µM) reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells and reduces tumor growth in a Mz-ChA-1 mouse xenograft model when administered at a dose of 10 mg/kg per day.{38346} O-1602 increases calcium mobilization and lipogenesis in 3T3-L1 adipocytes in a concentration-dependent manner and increases food intake and fat mass in rats; however, this effect was also observed in mice lacking GPR55.{38347} O-1602 reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain.{38344} It also decreases IL-6 and TNF-? levels and myeloperoxidase activities in the plasma, lungs, and pancreas in a mouse model of acute pancreatitis.{38345}

We also advise you